Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs DOI
Qinan Yin, Zhifeng Qu,

Regina Mathew

et al.

Cell Biochemistry and Function, Journal Year: 2024, Volume and Issue: 42(3)

Published: April 1, 2024

Abstract Breast cancer (BC) poses a persistent global health challenge, particularly in countries with elevated human development indices linked to factors such as increased life expectancy, education, and wealth. Despite therapeutic progress, challenges persist, the role of epitranscriptomic RNA modifications BC remains inadequately understood. The epitranscriptome, comprising diverse posttranscriptional on molecules, holds potential intricately modulate function regulation, implicating dysregulation various diseases, including BC. Noncoding RNAs (ncRNAs), acting regulators, influence physiological pathological processes, cancer. long noncoding (lncRNAs) microRNAs (miRNAs) add an extra layer gene expression control. This review delves into recent insights modifications, N‐6‐methyladenosine (m6A), adenine‐to‐inosine (A‐to‐I) editing, 5‐methylcytosine (m5C), specifically context lncRNA miRNAs BC, highlighting their implications progression. Understanding this intricate regulatory landscape is vital for deciphering molecular mechanisms underlying identifying targets.

Language: Английский

The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer DOI Creative Commons
Youqin Xu, Song Mu, Ziyang Hong

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)

Published: Jan. 7, 2023

Posttranscriptional modification of tumor-associated factors plays a pivotal role in breast cancer progression. However, the underlying mechanism remains unknown. M6A modifications cells are dynamic and reversible have been found to impact tumor initiation progression through various mechanisms. In this study, we explored regulatory cell proliferation metabolism m6A methylation Hippo pathway. METHODS: A combination MeRIP-seq, RNA-seq metabolomics-seq was utilized reveal map tissues cells. We conducted RNA pull-down assays, RIP-qPCR, MeRIP-qPCR, stability analysis identify relationship between proteins LATS1 regulation The expression biological functions were confirmed vitro vivo. Furthermore, investigated phosphorylation levels localization YAP/TAZ that activity pathway affected by RESULTS: demonstrated an important glycolytic factor, LATS1. METTL3 identified as writer, with YTHDF2 reader protein mRNA, which positive promoting both tumorigenesis glycolysis cancer. High induced mRNA. sites mRNA reduced its stability. Knockout or increased suppressed activating pathway.In summary, discovered METTL3-LATS1-YTHDF2

Language: Английский

Citations

58
The role of M6A modification in the regulation of tumor-related lncRNAs DOI Creative Commons
Yufei Lan,

Boyang Liu,

Hongbo Guo

et al.

Molecular Therapy — Nucleic Acids, Journal Year: 2021, Volume and Issue: 24, P. 768 - 779

Published: April 9, 2021

N6-methyladenosine (m6A) is the most abundant modification in eukaryotic cells, and it regulates RNA transcription, processing, splicing, degradation, translation. Long non-coding RNAs (lncRNAs), as transcriptional products with no or limited protein coding ability more than 200 nt length, play an important role epigenetic modification, mRNA stability, translation, other biological functions. Extensive studies have shown that both m6A lncRNAs are involved pathogenesis of various diseases, such kinds cancers, heart failure, Alzheimer's disease, periodontitis, human abdominal aortic aneurysm, obesity. To date, has been identified function enrichment regulation lncRNAs. In this review, we summarize tumor-related Moreover, discuss potential applications possible future directions field.

Language: Английский

Citations

65
The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implications DOI Creative Commons

Ziying Liu,

Lei Gao, Long Cheng

et al.

Experimental & Molecular Medicine, Journal Year: 2023, Volume and Issue: 55(3), P. 487 - 501

Published: March 1, 2023

Abstract N6-methyladenosine (m6A) is one of the epigenetic modifications RNA. The addition this chemical mark to RNA molecules regulates gene expression by affecting fate molecules. This posttranscriptional modification reversible and regulated methyltransferase “writers” demethylase “erasers”. m6A-modified RNAs depends on function different “readers” that recognize bind them. Research m6A methylation has recently increased due its important role in regulating cancer progression. Noncoding (ncRNAs) are a class transcribed from genome but whose roles have been overlooked their lack well-defined potential for translation into proteins or peptides. However, misconception now completely overturned. ncRNAs regulate various diseases, especially tumors, it confirmed they play either tumor-promoting tumor-suppressing almost all types tumors. In review, we discuss ncRNA summarize mechanisms involved. Finally, progress research clinical treatment significance

Language: Английский

Citations

37
Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions DOI Open Access
Rendy Hosea,

Sharon Hillary,

Shourong Wu

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(13), P. 3506 - 3506

Published: July 5, 2023

Cancer represents a significant and persistent global health burden, with its impact underscored by prevalence devastating consequences. Whereas numerous oncogenes could contribute to cancer development, group of transcription factors (TFs) are overactive in the majority tumors. Targeting these TFs may also combat downstream activated TFs, making them attractive potential targets for effective antitumor therapeutic strategy. One such TF is yin yang 1 (YY1), which plays crucial roles development progression various In preclinical studies, YY1 inhibition has shown efficacy inhibiting tumor growth, promoting apoptosis, sensitizing cells chemotherapy. Recent studies have revealed combining immunotherapy enhanced effects. However, clinical translation YY1-targeted therapy still faces challenges drug specificity delivery. This review provides an overview biology, role progression, as well strategies explored therapy, focus on their implications, including those using small molecule inhibitors, RNA interference, gene editing techniques. Finally, we discuss current limitations targeting need further research this area.

Language: Английский

Citations

31
Emerging role of RNA modification and long noncoding RNA interaction in cancer DOI Creative Commons
Liqiong Yang,

Lu Tang,

Qi Min

et al.

Cancer Gene Therapy, Journal Year: 2024, Volume and Issue: 31(6), P. 816 - 830

Published: Feb. 14, 2024

Abstract RNA modification, especially N6-methyladenosine, 5-methylcytosine, and N7-methylguanosine methylation, participates in the occurrence progression of cancer through multiple pathways. The function expression these epigenetic regulators have gradually become a hot topic research. Mutation regulation noncoding RNA, lncRNA, play major role cancer. Generally, lncRNAs exert tumor-suppressive or oncogenic functions its dysregulation can promote tumor metastasis. In this review, we summarize modifications lncRNAs. Furthermore, discuss relationship between modification lncRNA interaction various cancers. Therefore, review gives comprehensive understanding mechanisms by which affects cancers regulating lncRNAs, may shed new light on research provide insights into therapy.

Language: Английский

Citations

10
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives DOI Creative Commons
Fan Pan,

Xinrong Lin,

Liping Hao

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2021, Volume and Issue: 9

Published: May 11, 2021

Hepatocellular carcinoma (HCC) is the 6th most prevalent cancer and 4th leading cause of cancer-related death worldwide. Mechanisms explaining carcinogenesis HCC are not clear yet. In recent years, rapid development N 6 -methyladenosine (m6A) modification provides a fresh approach to disclosing this mystery. As mRNA in eukaryotes, m6A capable post-transcriptionally affect RNA splicing, stability, translation, thus participating variety biological pathological processes including cell proliferation, apoptosis, tumor invasion metastasis. METTL3 has been recognized as pivotal methyltransferase essential performance modification. can regulate expression m6A-dependent manner contribute carcinogenesis, progression, drug resistance HCC. present review, we going make summary known roles HCC, explicitly narrate potential mechanisms for these roles.

Language: Английский

Citations

34
The emerging role of RNA N6-methyladenosine methylation in breast cancer DOI Creative Commons
Fangchao Zheng, Feng Du, Jiuda Zhao

et al.

Biomarker Research, Journal Year: 2021, Volume and Issue: 9(1)

Published: May 27, 2021

Abstract N6-methyladenosine (m6A) modification is the most prevalent internal mRNA and involved in many biological processes eukaryotes. Accumulating evidence has demonstrated that m6A may play either a promoting or suppressing role breast cancer, including tumorigenesis, metastasis angiogenesis. In this review, we summarize latest research progress on function prognostic value of as well potential related therapeutic strategies.

Language: Английский

Citations

34
Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications DOI Creative Commons
Jinxin Tang, Jinhui Zhang, Lu Yu

et al.

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: April 17, 2023

Abstract N6-methyladenosine (m 6 A) is considered as the most common and important internal transcript modification in several diseases like type 2 diabetes, schizophrenia especially cancer. As a main target of m A methylation, long non-coding RNAs (lncRNAs) have been proved to regulate cellular processes at various levels, including epigenetic modification, transcriptional, post-transcriptional, translational post-translational regulation. Recently, accumulating evidence suggests that A-modified lncRNAs greatly participate tumorigenesis cancers. In this review, we systematically summarized biogenesis identified A-lncRNAs variety cancers, well their potential diagnostic therapeutic applications biomarkers targets, hoping shed light on novel strategies for cancer treatment.

Language: Английский

Citations

15
microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3 DOI Open Access
Yaqin Li, Tao Zhou, Xianyi Cheng

et al.

Bioengineered, Journal Year: 2022, Volume and Issue: 13(3), P. 4730 - 4743

Published: Feb. 20, 2022

Programmed death ligand 1 (PD-L1) plays an essential role in the development or progression of hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) are small RNA molecules that regulate gene expression during normal and pathophysiological events. Here, we explored functions detailed mechanisms miR-378a-3p PD-L1 HCC progression. First, was selected by analyzing miRNA levels two Gene Expression Omnibus datasets. We found exhibited a downward trend were negatively correlated with levels. Additionally, dual luciferase assay predicted directly targets PD-L1. Moreover, transfection mimics into Li-7 HuH-7 cells effectively decreased mRNA protein levels, inhibited Treg differentiation co-culture models modulating certain cytokines. Furthermore, overexpression hindered cell proliferation migration but facilitated apoptosis repressing STAT3 signaling cells. In conclusion, appears to inhibit tumorigenesis regulating Thus, may be potential target for therapy.

Language: Английский

Citations

20
Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications DOI
Xuan Liu, Xuelong Xie,

Chentao Sui

et al.

International Journal of Cancer, Journal Year: 2024, Volume and Issue: 154(11), P. 1877 - 1889

Published: March 1, 2024

Abstract In recent years, breast cancer (BC) has surpassed lung as the most common malignant tumor worldwide and remains leading cause of death in women. The etiology BC usually involves dysregulation epigenetic mechanisms aberrant expression certain non‐coding RNAs (ncRNAs). N6‐methyladenosine (m6A), prevalent RNA modification eukaryotes, widely exists ncRNAs to affect its biosynthesis function, is an important regulator tumor‐related signaling pathways. Interestingly, can also regulate or target m6A modification, playing a key role progression. However, m6A‐ncRNAs regulatory network not been fully elucidated, especially regulation by ncRNAs. Therefore, this review, we comprehensively summarize interaction biological significance modifications BC. Meanwhile, focused on clinical application value diagnosis prognosis, intending explore new biomarkers potential therapeutic targets.

Language: Английский

Citations

4